Highlight
- Young patients (≤50 years) undergoing surgery for intraductal papillary mucinous neoplasms (IPMNs) report excellent long-term health-related quality of life (HRQoL), comparable to the age-matched general population.
- Despite a considerable proportion requiring pancreatic enzyme replacement (63%) and insulin-dependent diabetes mellitus (16%), functional outcomes remain favorable post-resection.
- Parenchyma-sparing pancreatic resections are associated with more favorable long-term quality of life outcomes compared to more extensive procedures.
- Findings support early surgical intervention in young patients with IPMNs when clinically indicated, alleviating concerns about postoperative morbidity burden and long-term well-being.
Study Background
Intraductal papillary mucinous neoplasms (IPMNs) are cystic precursor lesions of the pancreas with malignant potential, increasingly detected incidentally and particularly in younger patient cohorts. The age group of ≤50 years represents a clinically relevant population given their longer life expectancy and concerns regarding the long-term consequences of pancreatic resection. Surgical management—ranging from parenchyma-sparing techniques to more extensive resections—carries risks of endocrine (e.g., diabetes mellitus) and exocrine insufficiency, raising questions about subsequent health-related quality of life (HRQoL). However, comprehensive longitudinal data on HRQoL, functional outcomes, and symptom burden specific to younger patients undergoing surgery for IPMNs have remained sparse. This study addresses an important knowledge gap by evaluating patient-reported outcomes over a median follow-up exceeding 7 years.
Study Design
This retrospective cohort study analyzed perioperative and long-term outcomes of 78 patients aged 50 years or younger who underwent surgical resection for IPMNs between 2004 and 2020. Data were acquired from a high-volume surgical center. Long-term follow-up including quality of life assessment was available for 56 patients (72%) at a median of 95 months post-surgery.
Surgical interventions included pancreaticoduodenectomy (54%), distal pancreatectomy (14%), total pancreatectomy (7%), enucleation (23%), and middle segment resection (2%). Histopathologic evaluation categorized lesions as intraductal papillary mucinous neoplasm-associated carcinoma (7%), high-grade dysplasia (25%), or low-grade dysplasia (68%).
Patient-reported quality of life was assessed using validated, disease-specific and general instruments – the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (general cancer QoL questionnaire) and the QLQ-PAN26 (pancreatic cancer–specific module). Endocrine and exocrine insufficiency were clinically characterized by insulin-dependent diabetes mellitus and pancreatic enzyme replacement therapy, respectively.
Key Findings
Patients had a median age of 46 years at surgery and were followed for nearly 8 years on average, providing robust long-term insights. Principal results include:
1. Quality of Life: Patients reported a global health status score of 71.1% on the QLQ-C30, indicating good perceived overall well-being. Functional domains scored highly at 82.9%, suggesting preserved physical, role, cognitive, emotional, and social functioning. Symptom burden was low overall (16.8%), with fatigue, insomnia, and diarrhea being the most commonly reported symptoms as per QLQ-PAN26.
2. Endocrine and Exocrine Function: Despite surgical impact, 63% required pancreatic enzyme supplementation and 16% had insulin-dependent diabetes mellitus, including 5 patients post-total pancreatectomy. This underscores the expected metabolic sequelae following pancreatic resection.
3. Impact of Surgical Type: Parenchyma-sparing procedures (e.g., enucleation) were associated with particularly favorable quality of life outcomes, reflecting the benefit of preserving pancreatic tissue.
4. Comparative Perspective: The QoL metrics closely aligned with those of the age-matched general German population, alleviating concerns that pancreatic resection in young patients leads to a significant long-term drop in health status.
These findings highlight that while metabolic consequences are frequent, they do not necessarily translate into diminished global HRQoL.
Expert Commentary
This study makes a seminal contribution by longitudinally characterizing the patient-centered outcomes of surgical intervention for IPMNs in a young demographic. The extended follow-up period strengthens the validity of the findings. Clinicians often debate early surgery versus surveillance for IPMNs due to oncologic risk and postoperative morbidity concerns; this data supports early surgical management when indicated, reassuring that long-term well-being remains high.
Limitations include the retrospective design and potential selection bias toward surgically fit patients. The single-center nature may restrict broad generalizability. Additionally, detailed analysis of factors influencing individual QoL domains, such as adjuvant therapies or psychological support, was not provided.
Mechanistically, parenchyma-sparing surgery preserves endocrine and exocrine reserve, explaining the better QoL outcomes—a principle increasingly emphasized in surgical oncology.
Conclusion
Young patients undergoing resection for IPMNs achieve remarkably favorable long-term quality of life, resembling that of their healthy peers despite the high prevalence of metabolic insufficiencies. Parenchyma preservation should be prioritized when oncologically appropriate. This evidence bolsters the rationale for timely surgical intervention in young patients with IPMNs and provides clinicians and patients with reassurance regarding postoperative quality of life during long-term survivorship.
Funding and Trial Registration
The referenced study did not explicitly report funding sources or clinical trial registration in the abstract. Further details should be sought from the full-text publication.
References
1. Rompen IF, Marstaller-Walz K, Hinz U, et al. Long-term quality of life after surgery for intraductal papillary mucinous neoplasms in young patients. Surgery. 2026 May 11;195:110216. PMID: 42114236.
2. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183-97.
3. Gupta R, Hebbar N, Lim S, et al. Health-related quality of life following major pancreatic surgery: a systematic review. HPB (Oxford). 2020;22(5):617-625.
This compilation of data offers a scientifically rigorous yet clinically applicable perspective on the long-term outcomes after pancreatic surgery for IPMN in younger adults, a critical subset warranting specialized considerations in surgical oncology and gastroenterology.
